Close Menu

More articles about Disease Areas

The company reported total revenues of RMB123.9 million ($18.2 million) for the quarter, driven largely by growth in its central laboratory business.

The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.

The company said that its Aptima HIV-1 molecular test utilizes a dual-target approach against highly conserved regions in the HIV genome.

The group noted that while molecular diagnostics are powerful tools, physicians' enthusiasm for such tests can lead to improper and excessive use.

NCI researchers performed a multi-platform study to elucidate the factors that can contribute to a patient's better-than-expected response to a drug.

The firm CE marked its RespiFinder 2Smart kit for SARS-CoV-2 and MERS-CoV testing, as well as the RealAccurate Quadriplex Flu/COVID-19 PCR kit.

As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.

At an AMP virtual meeting workshop, a Mayo Clinic lab director offered advice on what diseases to include, how to handle VUSs, and other considerations for ECS.

Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.

Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.

The firm said it will dispute the claim of overpayment and will separately negotiate with the undisclosed payor for in-network status.

In a conversation at the Association for Molecular Pathology meeting, the directors touched on topics such as test allocation and staffing and reagent shortages.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.

The company this month launched a lower priced benchtop instrument and a more versatile flagship product as well as a new intracellular protein assay.

Using tumor and matched normal sequence data generated for tens of thousands of cancer patients, the team identified mosaic cancer susceptibility in around one in 1,000 cases.

CPTAC researchers analyzed the genomes, proteomes, phosphoproteomes, and acetylproteomes of 122 treatment-naive breast cancer samples.

The deal joins Indivumed's collection of tissue biospecimens and immunohistochemistry expertise with Ultivue's multiplex immunofluorescence platform.

The company plans to increase the capacity of its CLIA-certified laboratory to about 100,000 SARS-CoV-2 tests per day by the end of 2020.

The glycoproteomics firm is using its mass spec platform for ovarian cancer and immunotherapy tests as well as service work for pharma and other partners.

The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.

Pages

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.